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Crizotinib (Xalkori) is an orally available, small molecule inhibitor of the ALK, ROS1 and c-MET tyrosine kinases. It is standard of care for the management of ALK-positive 
non-small cell lung cancer (NSCLC)1,2 and has activity in ROS1 rearranged NSCLC3 and 
c-MET amplified NSCLC.4 Accelerated approval of crizotinib by the U.S. Food and Drug 
Administration was granted in August 2011 for the treatment of advanced ALK-positive 
NSCLC on basis of a phase I and phase II trial, with initial data from 255 patients. Since 
then, crizotinib has been approved in approximately 78 countries and received by thousands 
of ALK-positive NSCLC patients worldwide.
Data from the initial clinical trials with crizotinib indicated that it was effective, safe, 
and generally well tolerated. In the phases 1, 2, and 3 studies of crizotinib, the most often 
reported adverse events were visual changes, nausea, diarrhea, vomiting, edema, constipa-
tion, and elevated transaminases.1,2,5,6 The most serious toxicities were hepatotoxicity and 
pneumonitis.1,2,5,6 As one would expect, with increasing clinical experience with crizotinib 
over recent years other toxicities have been described including asymptomatic bradycar-
dia7 and decreased total testosterone in males.6 In this issue of the Journal of Thoracic 
Oncology, information is provided on additional potential toxicity from crizotinib includ-
ing renal impairment, renal cysts, and hypersensitivity.
Impaired renal function associated with crizotinib treatment has previously been 
reported in recent case series.8–10 The largest of these by Brosnan et al8 describe a 23.9% 
mean reduction in estimated glomerular filtration rate (eGFR), calculated with Chronic 
Kidney Disease Epidemiology Collaboration method, in a series of 38 ALK-positive 
NSCLC patients treated with crizotinib. The majority of patients had complete recovery of 
eGFR to baseline upon cessation of crizotinib. The mechanism underlying the creatinine 
alteration and in particular if it was associated with a true nephrotoxicity or if it reflected a 
disproportional alteration in tubular creatinine secretion was unclear.
In this issue of the Journal of Thoracic Oncology, Camidge et al.11 attempt to shed 
light on the apparent changes in renal function based on detailed evaluation of two crizo-
tinib-treated individuals by serial calculation of eGFR using the Chronic Kidney Disease 
Epidemiology Collaboration equation in parallel with direct measurement of 24-hour cre-
atinine clearance or iothalamate assessment. Somewhat conflicting results were observed. 
In one patient, treatment with crizotinib resulted in a rise in serum creatinine and decrease 
in measured GFR. Cessation of crizotinib resulted in a fall in his serum creatinine and a 
rise both in his estimated GFR and his measured GFR. In a second patient, interruption of 
crizotinib treatment resulted in an increase in estimated GFR, but a rechallenge with crizo-
tinib was associated with a fall in eGFR but a rise in iothalamate-measured GFR. These 
results while observational and based on descriptions of only two patients, confirm that the 
rise in serum creatinine is reversible and that it may, or may not be, associated with a true 
alteration in renal function.
So what are the practical implications of dosing crizotinib in patients with impaired 
renal function? Guidance is provided by the crizotinib product information which indicates 
that no starting dose adjustment is required for patients with mild or moderate renal impair-
ment (creatinine clearance 30–89 ml/min) based on population pharmacokinetic analysis 
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that crizotinib exposure did not alter with this level of renal 
dysfunction.5 In patients with more significant renal impair-
ment (creatinine clearance <30 ml/min) increased exposure to 
crizotinib has been observed and the recommended starting 
dose is 250 mg once daily.5 In patients with documented renal 
impairment, or in patients noted to have rising creatinine on 
crizotinib treatment, avoidance of factors that may exacerbate 
renal impairment, e.g., concomitant use of nephrotoxic drugs 
seems appropriate. The data regarding the potential reversibil-
ity of creatinine alterations are reassuring and caution should 
be taken in ceasing crizotinib solely on basis of elevated cre-
atinine without additional measures of renal function.
Information about an additional renal toxicity of crizo-
tinib, namely the development of renal cysts, is provided 
by the report of Lin et al.12 While the development of renal 
cysts has been previously reported in the context of crizotinib 
treatment,5 Lin et al provide a retrospective review to indi-
cate that the frequency of cysts may be higher than previously 
suspected. In this study, 32 patients treated with crizotinib 
underwent radiological review of serial contrast-enhanced 
computed tomography scans done before and after initiation 
of crizotinib treatment. Curiously, a higher than expected 23 
of 32 (72%) had simple cysts on baseline scans (Bozniak 
category 1).13 Eight of 32 patients (7/32 with baseline cysts 
and 1/9 without) had an increase in number or size of cysts 
within the kidney with 4 of 32 developing complex renal cysts 
(Bozniak category II–IV).13 Importantly, cysts in three of five 
patients regressed on withholding crizotinib.
This report suggests that the renal cysts appear likely to 
be more frequent than the 4% described in the U.S. package 
insert5 and should enter the differential diagnosis for a patient 
on crizotinib treatment who develops simple or complex cysts 
on crizotinib treatment. The mechanism of cyst formation is 
uncertain and no biopsy information is provided to help elu-
cidate this. Further questions remain unanswered: What for 
example are the effects of age, sex, ethnicity or crizotinib con-
centration on frequency of cysts? It is reassuring, however, 
that the cysts are reversible after discontinuation of crizotinib. 
A separate report from Klempner et al14 describes a complex 
renal cyst on crizotinib that regressed despite continued ther-
apy with crizotinib.
Finally, Awad and collegues15 describe two cases of 
hypersensitivity to crizotinib. Hypersensitivity reactions to 
anticancer treatments commonly occur with cytotoxic drugs 
such as carboplatin or taxanes and monoclonal antibodies 
such as rituximab or cetuximab but hypersensitivity reac-
tions to small molecules have been reported less frequently. 
In this report, two cases of hypersensitivity to crizotinib char-
acterized by the eruption of a pruritic rash in the absence of 
other symptoms such as fever, hypotension, bronchospasm, or 
angioedema are described. While no skin testing results are 
provided, and the specific immunologic mechanisms respon-
sible for the hypersensitivity are not clear, in both patients it 
was possible to continue treatment with crizotinib after use 
of a 12-step desensitization protocol.16 Importantly, however, 
continued exposure to drug is required to maintain the state of 
tolerance induced by the desensitization, and once treatment 
is interrupted, rechallenge with drug may result in further 
hypersensitivity. While use of alternative ALK inhibitors may 
be an option for some patients, as the authors point out, the 
incidence of cross reactivity is unknown and the desensitiza-
tion protocol appears to be a reasonable and effective strategy 
to manage this apparently rare side effect allowing continued 
treatment with crizotinib.
An essential requirement of postmarketing pharmaco-
vigilance is reporting of adverse events by clinicians. It is 
through these mechanisms as well as by systematic collection 
of data by the drug sponsor and regulatory authorities that pre-
viously unrecognized adverse events or harmful drug interac-
tions be identified. The observational data provided in these 
reports in this issue of the Journal of Thoracic Oncology add 
to the clinical experience with crizotinib and help define the 
toxicity profile of crizotinib, albeit with small patient num-
bers. It appears, though, that the significant efficacy and safety 
profile that led to the initial accelerated approval of crizotinib 
has been maintained over time.
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